Population pharmacokinetics and pharmacodynamics of propofol in morbidly obese patients

Background and Objectives: In view of the increasing prevalence of morbidly obese patients, the influence of excessive total bodyweight (TBW) on the pharmacokinetics and pharmacodynamics of propofol was characterized in this study using bispectral index (BIS) values as a pharmacodynamic endpoint. Methods: A population pharmacokinetic and pharmacodynamic model was developed with the nonlinear mixed-effects modelling softwareNONMEMVI, on the basis of 491 blood samples from 20 morbidly obese patients (TBW range 98-167 kg) and 725 blood samples from 44 lean patients (TBW range 55-98 kg) from previously published studies. In addition, 2246 BIS values from the 20 morbidly obese patients were available for pharmacodynamic analysis. Results: In a three-compartment pharmacokinetic model,TBWproved to be the most predictive covariate for clearance from the central compartment (CL) in the 20 morbidly obese patients (CL 2.33L/min × [TBW/70] [0.72]). Similar results were obtained when the morbidly obese patients and the 44 lean patients were analysed together (CL 2.22L/min × [TBW/70] [0.67]). No covariates were identified for other pharmacokinetic parameters. The depth of anaesthesia in the morbidly obese patients was adequately described by a two-compartment biophase-distribution model with a sigmoid maximum possible effect (E _max) pharmacodynamic model (concentration at half-maximum effect [EC50] 2.12mg/L) without covariates. Conclusion: We developed a pharmacokinetic and pharmacodynamic model of propofol in morbidly obese patients, in which TBW proved to be the major determinant of clearance, using an allometric function with an exponent of 0.72. For the other pharmacokinetic and pharmacodynamic parameters, no covariates could be identified.